{
  "source_file": "syk-20250930.htm",
  "form_type": "10-Q",
  "item1_clean": null,
  "item7_clean": null,
  "item2_clean": "EPS\nReported percent net sales\nAcquisition and integration-related costs:\nInventory stepped-up to fair value\nOther acquisition and integration-related (a)\nAmortization of purchased intangible assets\nStructural optimization and other special charges (b)\nGoodwill and other impairments (c)\nMedical device regulations (d)\nRecall-related matters (e)\nRegulatory and legal matters (f)\nAdjusted percent net sales\n(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:\nEmployee retention and workforce reductions\nChanges in the fair value of contingent consideration\nManufacturing integration costs\nStock compensation payments upon a change in control\nOther integration-related activities\nAdjustments to Operating Income\nOther income taxes related to acquisition and integration-related costs\nAdjustments to Income Taxes\nAdjustments to Net Earnings\n(b) Structural optimization and other special charges represent the costs associated with:\nEmployee retention and workforce reductions\nClosure/transfer of manufacturing and other facilities\nTermination of sales relationships in certain countries\nAdjustments to Operating Income\nAdjustments to Other Income (Expense), Net\nAdjustments to Income Taxes\nAdjustments to Net Earnings\n(c) Goodwill and other impairments represent the costs associated with:\nCertain long-lived and intangible asset write-offs and impairments\nProduct line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs)\nAdjustments to Operating Income\nAdjustments to Income Taxes\nAdjustments to Net Earnings\n(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device\nreporting regulations and other requirements of the new medical device regulations in the European Union.\n(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to\nresolve certain recall-related matters.\n(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to\nresolve certain regulatory or other legal matters and the amount of favorable awards from settlements.\nDollar amounts are in millions except per share amounts or as otherwise specified.\nSTRYKER CORPORATION\n\n(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:\nAdjustments related to the transfer of certain intellectual properties between tax jurisdictions\nAdjustments to Income Taxes\nAdjustments to Other Income (Expense), Net\nAdjustments to Net Earnings\nReconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures\nEPS\nReported percent net sales\nAcquisition and integration-related costs:\nInventory stepped-up to fair value\nOther acquisition and integration-related (a)\nAmortization of purchased intangible assets\nStructural optimization and other special charges (b)\nGoodwill and other impairments (c)\nMedical device regulations (d)\nRecall-related matters (e)\nRegulatory and legal matters (f)\nAdjusted percent net sales\nEPS\nReported percent net sales\nAcquisition and integration-related costs:\nInventory stepped-up to fair value\nOther acquisition and integration-related (a)\nAmortization of purchased intangible assets\nStructural optimization and other special charges (b)\nGoodwill and other impairments (c)\nMedical device regulations (d)\nRecall-related matters (e)\nRegulatory and legal matters (f)\nAdjusted percent net sales\n(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:\nTermination of sales relationships\nEmployee retention and workforce reductions\nChanges in the fair value of contingent consideration\nManufacturing integration costs\nStock compensation payments upon a change in control\nOther integration-related activities\nAdjustments to Operating Income\nOther income taxes related to acquisition and integration-related costs\nAdjustments to Income Taxes\nAdjustments to Net Earnings\nDollar amounts are in millions except per share amounts or as otherwise specified.\nSTRYKER CORPORATION\n\n(b) Structural optimization and other special charges represent the costs associated with:\nEmployee retention and workforce reductions\nClosure/transfer of manufacturing and other facilities (e.g., site closure, contract termination and redundant employee costs)\nProduct line exits (e.g., inventory, long-lived asset and specifically-identified intangible asset write-offs)\nTermination of sales relationships in certain countries\nAdjustments to Operating Income\nAdjustments to Income Taxes\nAdjustments to Other Income (Expense), Net\nAdjustments to Net Earnings\n(c) Goodwill and other impairments represent the costs associated with:\nCertain long-lived and intangible asset write-offs and impairments\nProduct line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs)\nAdjustments to Operating Income\nAdjustments to Income Taxes\nAdjustments to Net Earnings\n(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device\nreporting regulations and other requirements of the new medical device regulations in the European Union.\n(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to\nresolve certain recall-related matters.\n(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to\nresolve certain regulatory or other legal matters and the amount of favorable awards from settlements.\n(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:\nAdjustments related to the transfer of certain intellectual properties between tax jurisdictions\nCertain tax audit settlements\nAdjustments to Income Taxes\nAdjustments to Other Income (Expense), Net\nAdjustments to Net Earnings\nFINANCIAL CONDITION AND LIQUIDITY\nNet cash provided by (used in):\nOperating activities\nInvesting activities\nFinancing activities\nEffect of exchange rate changes\nChange in cash and cash equivalents\nOperating Activities\n\nGeographic and Segment Net Sales\nMedSurg and Neurotechnology\nSupplemental Net Sales Growth Information\nNote: In the first quarter\nwe changed the name of our Neurovascular business to Vascular due the acquisition of Inari. In the fourth\n\nquarter 2024 we reorganized our Spine business to align with certain updates to our internal reporting structure. The spine enabling\n\nper diluted share for the respective period.\nReconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures\nEPS\nReported percent net sales\nAcquisition and integration-related costs:\nInventory stepped-up to fair value\nOther acquisition and integration-related (a)\nAmortization of purchased intangible assets\nStructural optimization and other special charges (b)\nGoodwill and other impairments (c)\nMedical device regulations (d)\nRecall-related matters (e)\nRegulatory and legal matters (f)\nAdjusted percent net sales\nDollar amounts are in millions except per share amounts or as otherwise specified.\nSTRYKER CORPORATION\n\nmost directly comparable GAAP financial measure.\nCONSOLIDATED RESULTS OF OPERATIONS\nResearch, development and engineering expenses\nSelling, general and administrative expenses\nAmortization of intangible assets\nGoodwill and other impairments\nOther income (expense), net\nNet earnings per diluted share\nAdjusted net earnings per diluted share\nDollar amounts are in millions except per share amounts or as otherwise specified.\nSTRYKER CORPORATION\n\n. The key components of the change were:\nManufacturing and supply chain costs\nStructural optimization and other special charges\nInventory stepped up to fair value\nWhile segment mix was not a significant driver of the change in\n\n. The key components of the change were:\nManufacturing and supply chain costs\nStructural optimization and other special charges\nInventory stepped up to fair value\nGross profit as a percentage of net sales in the\n\nITEM 2.\nMANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS\nABOUT STRYKER\nStryker is a global leader in medical technologies and, together\n\n$650M\nsenior unsecured notes.\nRefer to \"Non-GAAP Financial Measures\" for a discussion of non-\nGAAP financial measures used in this report and a reconciliation to the\n\nManufacturing and supply chain costs\nResearch, development and\nengineering expenses\nSelling, general and administrative\nin MedSurg and Neurotechnology operating\n\nManufacturing and supply chain costs\nResearch, development and\nengineering expenses\nSelling, general and administrative\nin MedSurg and Neurotechnology operating\n\nNeurotechnology segment than our Orthopaedics segment.\nResearch, Development and Engineering Expenses\nResearch, development and engineering expenses\n\nestimates from those disclosed in our Annual Report on Form 10-\n, except as follows.\nRefer to Note 11 to our Consolidated Financial Statements for\n\ntechnologies portfolio (Enabling Technologies) was reclassified to Other Orthopaedics, the interventional spine portfolio was reclassified\n\nNeurotechnology businesses and most Orthopaedics businesses.\nMedSurg and Neurotechnology Net Sales\nMedSurg and Neurotechnology net sales\n\nacquisition-related tax items.\nDollar amounts are in millions except per share amounts or as otherwise specified.\nSTRYKER CORPORATION\n\nintention or obligation to publicly update or revise any forward-\nlooking statement to reflect any change in our expectations or in\n\ntime-to-time. We continue to have str"
}